Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM)

NCT03332173 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

44

Enrollment

INDUSTRY

Sponsor class

Conditions

Waldenström's Macroglobulinemia (WM)

Interventions

DRUG: Zanubrutinib

Sponsor

BeiGene